UK Pharmacovigilance: Sending and Receiving Information on Adverse Drug Reactions

1. Purpose of ADR information exchange

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance on how marketing authorisation holders (MAHs) and other stakeholders should send and receive information on adverse drug reactions (ADRs) to ensure ongoing monitoring and safety of medicines. ADRs are unintended, harmful responses to medicinal products, and reporting them is a key component of pharmacovigilance. Source: Send and receive information on adverse drug reactions (ADRs) (gov.uk)

2. Reporting requirements for MAHs

Marketing authorisation holders are required to submit all UK individual case safety reports (ICSRs) and serious non-UK ICSRs directly to the MHRA through designated systems such as the ICSR Submissions portal or the Gateway. For reports relating to Northern Ireland, the country code “XI” should be used for MHRA submissions. The MHRA accepts both E2B R2 and R3 XML formats and ensures conversion where necessary. Source: Send and receive information on adverse drug reactions (ADRs) (gov.uk)

3. New MHRA systems

The MHRA has updated its adverse incident database to comply with the ICH ICSR R3 standard. After the upgrade, all ICSRs and acknowledgements sent via the Gateway or portal will be in the R3 format, though R2 XMLs continue to be accepted and converted. MAHs should ensure their systems can handle R3 compliance to receive files effectively from the MHRA. Source: Send and receive information on adverse drug reactions (ADRs) (gov.uk)

4. Literature monitoring and signal notifications

While the MHRA does not publish a literature monitoring list, MAHs are responsible for conducting relevant literature searches and sending reports of findings to the MHRA, including those from services such as the EMA’s Medical Literature Monitoring. Additionally, standalone safety signal notifications may be submitted using a dedicated form to the MHRA’s signal management team. Source: Send and receive information on adverse drug reactions (ADRs) (gov.uk)

5. Role of the Yellow Card Scheme

The UK’s Yellow Card Scheme is the primary spontaneous reporting system for ADRs, enabling healthcare professionals, patients, parents and carers to submit reports of suspected ADRs for medicines, vaccines and other healthcare products. Reports contribute to national pharmacovigilance and help detect safety signals that may lead to regulatory action. Source: Yellow Card Scheme (wikipedia.org)

6. Signal detection and regulatory action

A safety signal is information suggesting a new or known adverse event may be linked to a medicine and warrants further investigation. The MHRA evaluates signals using ADR data and may take appropriate regulatory action to protect public health, with MAHs participating in signal reporting and follow-up processes. Source: UK MHRA: Guidance on Send and Receive information on Adverse Drug Reactions (ADRs) (regulatoryaffairsnews.com)

7. Confidentiality and data security

The guidance emphasizes that data submitted and received as part of ADR reporting should maintain confidentiality and security to protect the privacy of individuals involved. This includes safeguarding personal data while enabling effective pharmacovigilance communication. Source: UK MHRA: Guidance on Send and Receive information on Adverse Drug Reactions (ADRs)

8. Integration with pharmacovigilance processes

ADR reporting and information exchange form part of a broader pharmacovigilance system that ensures ongoing monitoring of medicine safety throughout the life cycle of a product on the market. Coordinated efforts between MAHs, healthcare professionals, and the MHRA help mitigate risks associated with medicinal products. Source: Send and receive information on adverse drug reactions (ADRs)